, a novel proteasome inhibitor, has been found to possess potent growth inhibition in human multiple myeloma cells. To enhance its therapeutic effects, we established TP-110-resistant RPMI-8226 (RPMI-8226/ TP-110) cells and elucidated their resistance mechanisms. The IC 50 value for TP-110 cytotoxicity in the RPMI-8226/TP-110 cells was about 10-fold higher than that of the parental sensitive cells. The RPMI-8226/TP-110 cells exhibited distinct drug resistance to other proteasome inhibitors. Furthermore, they showed high cross-resistance to the cytotoxic effects of doxorubicin, etoposide, taxol, and vincristine. P-glycoprotein (MDR1), encoded by ABCB1, was elevated in the RPMI-8226/TP-110 cells, and the MDR1 inhibitor verapamil overcame their resistance to TP-110. The results of DNA microarray and RT-PCR suggested that the expression of ABCB1 is significantly elevated in RPMI-8226/TP-110 cells. This indicates that resistance in RPMI-8226/TP-110 cells is involved in the expression of P-glycoprotein, a drug-efflux pump.
The ubiquitin-proteasome system is involved in the cell cycle, signal transduction, the cellular stress response, and the immune response. 1) Because cancer cells are more highly proliferative than normal cells, their protein translation and degradation is also higher. 2) Accordingly, inhibitors of the proteasome represent a promising group of chemotherapeutic agents for cancer treatment.
Previous research has demonstrated that MG-132, lactacystin, and bortezomib have proteasome inhibitory activities. [3] [4] [5] Bortezomib, a dipeptide boronic acid, shows significant anti-tumor activity in multiple myeloma cells. In 2003, the U.S. Food and Drug Administration (FDA) approved bortezomib (VELCADEÔ), formerly known as PS-341, for the treatment of relapsed/ refractory multiple myeloma. 6) We have reported the isolation of a new proteasome inhibitor, tyropeptin A, produced by Kitasatospora sp. MK993-dF2. [7] [8] [9] [10] In an effort to enhance its inhibitory potency, a structural model of tyropeptin A bound to the site responsible for chymotrypsin-like activity of the mammalian 20S proteasome was constructed. Based on these modeling experiments, several derivatives were synthesized. One of them, TP-110, specifically inhibits chymotrypsin-like activity, but does not inhibit the postglutamyl-peptide hydrolyzing (PGPH) and trypsin-like activities of the 20S proteasome.
11) TP-110 strongly inhibits the growth of human tumor cells and induces apoptosis. 12) One of the mechanisms of apoptosis induction by TP-110 is down-regulation of inhibitors of apoptosis proteins (IAPs) in multiple myeloma cells. 13) A loss of anti-tumor efficacy responsible for drugresistance in cells is known in cancer chemotherapy. ABC (ATP binding cassette) transporters are well-known multi-drug efflux transporters that depend on ATP. 14) One of these, ABCB1 (MDR1), is a representative transporter involved in human multi-drug resistant tumor cells. In addition to ABCB1, expression of ABCC1 (MRP1) and ABCG2 (BCRP) has also been found in tumor cell lines. [15] [16] [17] To overcome multi-drug resistance (MDR), MDR inhibitors have been developed. Verapamil, cyclosporin A and tamoxifen are first-generation MDR inhibitors, 18) and the next generation of inhibitors and antibodies for MDR are now being studied. 19) These inhibitors or antibodies might significantly contribute to overcoming anticancer drug resistance.
We have been developing novel proteasome inhibitors as candidate anti-tumor agents. To strengthen their therapeutic effects, we have also been investigating methods of overcoming resistance. Here we report the involvement of ABCB1 in the resistance mechanisms of RPMI-8226/TP-110 cells.
Materials and Methods
Chemicals and antibodies. TP-110, a tyropeptin A derivative, was synthesized at the Numazu Bio-Medical Research Institute, Numazu, Japan.
9) It was dissolved in DMSO (10 mg/ml), stored at À20 C, and diluted with PBS (pH 7.4). The chemical structure of TP-110 is shown in Fig. 1 . MG-132 and lactacystin were purchased from the Peptide Institute (Osaka, Japan). Bortezomib was synthesized at the Microbial Chemistry Research Institute (Tokyo, Japan). Anti-cancer drugs were purchased from Sigma (St. Louis, MO). Antibodies were obtained as follows: rabbit anti-caspase-3 (sc-7148) and rabbit anti-mdr (sc-8313) (Santa Cruz Biotechnology, Santa Cruz, CA); mouse anti-cytochrome c (7H8.2C12) (BD BioScience, San Diego); mouse anti--tubulin (B-5-1-2) (Sigma); and mouse anti-mrp1 (QCRL-1) (Chemicon International, Temecula, CA).
Cells and establishment of TP-110-resistant cells. Human multiple myeloma RPMI-8226 cells were purchased from ATCC. Initial induction of resistant cells were achieved by continuous exposure of RPMI-8226 cells to TP-110 (10 ng/ml) over 3 months. Growing resistant cells were further treated with gradually increasing conceny To whom correspondence should be addressed. Fax: +81-55-922-6888; E-mail: iijimam@bikaken.or.jp Abbreviations: ABC, ATP binding cassette; MDR, multidrug resistance; P-gp, P-glycoprotein; IAPs, intrinsic inhibitor of apoptosis proteins trations of TP-110 (up to a final concentration of 100 ng/ml for RPMI-8226 cells). The resistant RPMI-8226 cells that survived exposure to TP-110 (100 ng/ml) were cloned by the limiting dilution method. Chronic leukemia K-562 cells and doxorubicin-resistant K-562 (K-562/DOX) cells were provided by Dr. Setsuko Kunimoto at our laboratory. Cells were grown in RPMI1640 medium supplemented with 10% FBS, 100 U/ml of penicillin G, and 100 mg/ml of streptomycin at 37 C with 5% CO 2 .
Proteasome activity. The chymotrypsin-like activity of the 20S proteasome was measured using a fluorogenic substance, as described previously.
7) The 20S proteasome was prepared from RPMI-8226 and RPMI-8226/TP-110 cells.
Cytotoxicity. Cells (1 Â 10 4 ) were cultured in 96-well plates with a test sample. Cells from 72 h culture were pulsed with MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) for 4 h, and were incubated in the presence of 10% SDS for 20 h. Absorbance was measured at 570 nm using a spectrophotometer (Dainippon Sumitomo Pharma, Osaka, Japan).
Cell cycle analysis. Cells (1 Â 10 4 ) were cultured with and without 0.1 mg/ml TP-110 for 24 h. Cells fixed using 70% ethanol were treated with 0.1% RNase A at 37 C for 15 min, and were then incubated with propidium iodide (PI). DNA fluorescence was analyzed using a fluorescence-activated cell sorter (FACSCalibur; BD Bioscience, Franklin Lakes, NJ).
Caspase-3 activity. Cells (5 Â 10 5 ) were cultured with TP-110 for 24 h, washed twice with PBS, and lysed in cell extraction buffer containing 50 mM HEPES (pH 7.4), 5 mM CHAPS, and 5 mM DTT, and were stored at À80 C. Cell extracts were centrifuged at 14;000 Â g for 10 min at 4 C, and the caspase-3 activity of the supernatant was assessed with a caspase-3 assay kit (Sigma). This assay is based on the hydrolysis of a peptide substrate, acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (Ac-DEVD-AMC), by caspase-3. After incubation at 37 C for 30 min, fluorescence intensity (excitation and emission wavelengths of Ac-DEVD-AMC, 380 nm and 460 nm respectively) was measured with Fluoroskan II (Dainippon Sumitomo Pharma, Osaka, Japan).
Western blot analysis. Cultured cells were harvested, washed twice with PBS, and suspended in lysis buffer containing 20 mM HEPES (pH 7.5), 150 mM NaCl, 1% Triton X-100, 10% glycerol, 1 mM EDTA, 50 mM NaF, 50 mM -glycerophosphate, 1 mM Na 3 VO 4 , 25 mg/ml of antipain, 25 mg/ml of leupeptin and 25 mg/ml of pepstatin at 4 C for 15 min. After centrifugation at 15,000 rpm, the supernatant was assessed using a Bio-Rad protein assay kit (Bio-Rad, Hercules, CA). The cytosol fraction was extracted at 4 C for 5 min using digitonin lysis buffer containing 10 mM HEPES, 0.3 M mannitol 0.1% BSA, and 0.1 mM digitonin, and centrifuged at 8;500 Â g for 5 min at 4 C. Equal amounts of the protein extract were subjected to SDS-PAGE. The isolated protein was then transferred onto an Immobion PVDF membrane (Millipore, Bedford, MA). The membrane was blocked with 5% non-fat milk in Tris-buffered saline containing 0.1% Tween 20 (TBS-T) for 60 min. After washing with TBS-T, the membrane was incubated with primary antibody in blocking solution for 60 min at room temperature. After further washing with TBS-T, the membrane was then incubated with secondary antibody (anti-rabbit or anti-mouse immunoglobulin-horseradish peroxidase) for 30 min. The protein detected was visualized by the enhanced chemiluminescence reaction (ECL) procedure (GE Healthcare UK, Chalfont, UK).
RT-PCR analysis. Total RNA was isolated from the cells using an RNeasy Kit (Qiagen, Valencia, CA). cDNA was prepared from total RNA using a Reverse Transcription System (Promega, Madison, WI). PCR was conducted using Promega PCR Master Mix (Promega) and a pair of specific primers. The primers used were as follows: ABCB1-sense 5
0 -AGAGGATCGCCATTGCGCGT-3 0 and ABCB1-antisense
0 and ABCC1-antisense GAGGTAGAG-AGCAAGGTAGACTTGC-3 0 ; and GAPDH-sense 5 0 -GATGACATC-AAGAAGGTGGTGAA-3 0 and GAPDH-antisense 5 0 -GTCTTACTCC-TTGGAGGCCTAGT-3 0 . The PCR products were electrophoresed on 2% agarose gels, and were detected by SYBR Green I nucleic acid gel staining (Molecular Probes, Eugene, OR).
cDNA microarray analysis. Labeled antisense RNA was prepared from the total RNA of the cells using of an RNA Transcript Sure LABEL Core Kit (Takara Bio, Ohtsu, Japan) with Cy3-and Cy5-dUTP (GE Healthcare, Piscataway, NJ). The cDNA microarray system used the IntelliGene HS Human Expression CHIP, which contains 16,600 spots of cDNA sequences. Microarrays were scanned using a 428-Array Scanner (Affymetrix, Santa Clara, CA).
Results
Establishment of RPMI-8226/TP-110 cells RPMI-8226/TP-110 cells were developed over a 9-month period by continuous stepwise exposure to increasing concentrations of TP-110, and 10 clones were isolated by the limiting dilution method. The IC 50 value for TP-110 cytotoxicity in the RPMI-8226/TP-110 cells showed a 9 to 24-fold increase as compared to the parental sensitive cells. Among these, we selected three strains (clone 2, clone 5, and clone 7), that exhibited distinct indices of resistance ( Table 1) .
Characteristics of the RPMI-8226/TP-110 cells
The morphology of RPMI-8226/TP-110 cells did not change as compared to the parent cells. Although the endogenous proteasome activities of RPMI-8226/ TP-110 increased 1.4 to 1.6 fold, the sensitivity of the proteasome to TP-110 in the RPMI-8226/TP-110 cells were similar to that of the parent cells ( Fig. 2A and B) . Previous studies have indicated that TP-110 induced apoptosis in RPMI-8226 cells at 12 nM.
11) The effects of TP-110 on the cell cycle of the parent and the resistant cells are shown in Fig. 3A . Treatment with TP-110 for 24 h increased the number of cells in sub-G 1 and decreased the number of cells in G 1 and G 2 M on the parent sensitive cells. However, the RPMI-8226/TP-110 cells were tolerant of TP-110 (Fig. 3A) . Similarly, the addition of TP-110 to the parent sensitive cells strongly released cytochrome c into the cytosol, induced the active form of caspase-3, and increased caspase-3 activity, but the addition of TP-110 to RPMI-8226/ TP-110 cells did not produce similar results (Fig. 3B, C,  and D) . This suggests that RPMI-8226/TP-110 cells are tolerant TP-110.
Cross-resistance pattern of RPMI-8226/TP-110 cells Drug-resistant cells often exhibit cross-resistance to other drugs. First, we examined the cross-resistance to other proteasome inhibitors of RPMI-8226/TP-110 cells. The RPMI-8226/TP-110 cells showed crossresistance to MG-132 (2.9 to 3.5 fold) and bortezomib (1.4 to 2.1 fold), but these cells showed no crossresistance to lactacystin. Second, the cross-resistance to several anticancer drugs of RPMI-8226/TP-110 cells was examined. The RPMI-8226/TP-110 cells were also cross-resistant to DNA-interacting drugs, mitosis blocking drugs, topo II inhibitors, and anti-metabolite drugs. In particular, they showed potent cross-resistance to doxorubicin (40 to 115 fold), taxol (375 to 500 fold), vincristine (212 to 253 fold), and etoposide (202 to 396 fold) ( Table 2) .
DNA microarray analysis
DNA microarray analysis is informative in elucidating the mechanisms of drug action. Parent RPMI-8226 cells and RPMI-8226/TP-110 cells were incubated in fresh medium for 24 h, and total RNA was then extracted from the control (parent) and the experimental (resistant) cells. The changes in mRNA expression in the RPMI-8226/TP-110 cells are shown in Table 3 . ABCB1, FLJ10178, HSPB8, CCL2, AUTS2, RPIB9, ZNF521, CYP24A1, CFC1, and BTBD3 showed increased expression in the resistant cells, while FN1, SLC27A2, TOM1L1, EPDR1, CADPS2, KIAA0802, STARD3NL, HMGA2, FLJ14564, and DMRT2 showed decreased expression. Among those genes showing altered expression, ABCB1 is known to be involved in MDR. The expression levels of 44 ABC transporter genes are shown in Table 4 . Among the ABC transporters examined, only ABCB1 showed higher expression. This suggests that the ABCB1 transporter is profoundly involved in the mechanism of drug resistance in RPMI-8226/TP-110 cells.
Expression of ABCB1 in RPMI-8226/TP-110 cells
Expression of ABCB1 in the RPMI-8226/TP-110 cells was confirmed by RT-PCR and Western blotting. ABCB1 expression was markedly elevated in these cells, but the expression of ABCC1 (MRP1) was not elevated as to mRNA and protein levels ( Fig. 4A and B) .
Effects of ABC transporter inhibitors on RPMI-8226/ TP-110 cells
In order to determine whether the ABCB1 transporter is involved in the resistance mechanism in the RPMI-8226/TP-110 cells, we examined the effects of an ABC transporter inhibitor. The addition of verapamil, wellknown to be an ABC transporter antagonist, reversed not only TP-110 resistance, but also the MG-132, bortezomib, and doxorubicin resistance in the RPMI-8226/ TP-110 cells (Table 5) . Additionally, we examined the effects of other MDR1 inhibitors and other a Ca antagonists (diltiazem and nifedipine) did not (Supplemental Table 1 ; see Biosci. Biotechnol. Biochem. Web site). This suggests that resistance in RPMI-8226/ TP-110 cells depends on the expression of ABCB1.
Effects of TP-110 on the K-562/DOX cells
Resistance to TP-110 in another cell line that expresses ABCB1 was then investigated. K-562/DOX cells showed high expression of ABCB1, but K-562 (parent) cells did not (Supplemental Fig. 1 ; see Biosci. Biotechnol. Biochem. Web site). Predictably, the K-562/ DOX cells showed strong resistance to TP-110. With regard to other proteasome inhibitors, K-562/DOX cells showed resistance to MG-132 and bortezomib, similarly to the RPMI-8226/TP-110 cells, while they were not resistant to lactacystin (Tables 2 and 6 ).
Discussion
In cancer drug discovery, the proteasome is a promising molecular target. 5) In addition to the treatment of relapsed or refractory multiple myeloma, bortezomib is also undergoing clinical trials for the treatment of several cancers (e.g., prostate). 20) TP-110 ( Fig. 1 ) strongly inhibits the growth of various human cell lines and induces apoptosis in their cells. 12) In order to strengthen its therapeutic effects, we established RPMI-8226/TP-110 cells and elucidated their resistance mechanisms.
Our results suggest that the factor involved in resistance of the RPMI-8226/TP-110 cells is ABCB1. DNA microarray is a useful tool to estimate changes in gene expression in cells. Our analytical results indicate that ABCB1 is overexpressed in RPMI-8226/TP-110 cells (Table 3 ). The results of Western blotting and RT-PCR support the results of DNA microarray analysis. The addition of verapamil (10 mg/ml) reversed resistance in RPMI-8226/TP-110 cells (Table 5) . Furthermore, K-562/DOX cells expressing ABCB1 also showed strong resistance to TP-110 as compared to MG-132 and bortezomib (Table 6) Fig. 3 . Characteristics of the RPMI-8226/TP-110 Cells. Cells were incubated with 0.1 mg/ml TP-110. A, After 24 h, the cells were examined by flow cytometry. B, Cells were incubated with 0.1 mg/ ml TP-110. After 10, 24, and 48 h, the cytosol fraction of the cells was extracted using digitonin lysis buffer. C, After 24 h, Western blot analysis was performed using whole cell lysates, as described in ''Materials and Methods.'' D, After 24 h, the caspase-3 activity of whole-cell lysates was assessed as described in ''Materials and Methods. '' were resistant to lactacystin. This susceptibility depends on the physico-chemical properties of the compound, including its hydrophobicity and molecular weight. 21, 22) Resistance to chemotherapeutic agents is a significant problem in the treatment of cancer. 14) Colchicine, On DNA microarray analysis, 44 ABC transporters were investigated. As shown in Table 4 , ABCB1 was strongly overexpressed and ABCG1 was slightly overexpressed in RPMI-8226/TP-110 cells. Conversely, ABCG8 was repressed in the RPMI-8226/TP-110 cells. ABCG1 is reported to regulate the functions of macrophage cholesterol and phospholipid transport in Drosophila, 18) but the functions of these genes in humans are not known.
Drug resistance can be avoided by inhibiting the function of transporters induced by chemotherapy. Verapamil in breast cancer and non-small cell lung carcinoma and cyclosporin A in acute myeloid leukemia have shown benefits in clinical trials. 23) A third generation of inhibitors, including PSC833 and MS-209, are now being developed. 19) Therefore, combination therapy with TP-110 and an ABCB1 inhibitor might produce beneficial effects in vivo.
Inconsistent findings involving proteasome inhibitors and P-gp have been reported. Bortezomib and MG-132, proteasome inhibitors, reportedly reduced the degree of the MDR in MCF-7/DOX cells, 24) and MG-132 apparently reversed the MDR of gastric cancer by inhibiting P-gp. 25) These findings suggest that proteasome inhibitors attenuate the expression of P-gp and induce apoptosis in resistant tumor cells. On the other hand, the proteasome inhibitors bortezomib and MLN273 are substrates of P-gp in leukemic cells, and knockdown of P-gp resensitizes cells against these inhibitors.
26)
Ohkawa et al. reported a possible role of calpain in P-gp turnover. 27) In the RPMI-8226/TP-110 cells, our results clearly indicate that a proteasome inhibitor, TP-110, is the substrate of ABCB1 (P-gp).
In conclusion, results of the present study indicate that the resistance factor in established RPMI-8226/TP-110 cells is ABCB1. Overexpression of ABCB1 in the RPMI-8226/TP-110 cells was indicated by the results of DNA microarray analysis, and was supported by the results of RT-PCR and Western blotting. Moreover, the addition of an ABCB1 inhibitor, verapamil, reversed resistance in the RPMI-8226/TP-110 cells. These results suggest that TP-110 therapy requires such inhibitors to overcome resistance via P-gp. Chemical modification of TP-110 and/or combination therapy with an ABCB1 inhibitor is a promising approach in cancer chemotherapy. 
